Stephen D. Miller, Ph.D., is the Judy Gugenheim Research Professor of Microbiology–Immunology at Northwestern University Feinberg School of Medicine. Dr. Miller has spent 32 years as a faculty member at Northwestern, where his research focuses on understanding the mechanisms underlying the pathogenesis and immunoregulation of autoimmune diseases, allergic disease, and rejection of tissue and organ […]
For people living with type 1 diabetes (T1D), establishing insulin independence by implanting insulin-producing beta cells into the body would be life changing. But a challenge to this potential therapy lies in the body’s immune system, which recognizes the implanted beta cells as foreign entities or invaders and subsequently attacks them. Furthermore, the implanted beta […]
Taking oral insulin in combination with low-dose anti-CD3 results in long-term reversal of type 1 diabetes in mice whose immune systems specifically attack insulin. The findings, if translated to humans, would help not only to identify people who are most likely to benefit from the therapy, but also to determine whether the therapy is working.
By Thania Benios In the 19th and early 20th centuries, diphtheria, measles, and mumps were frightening household names. Each year in the United States, these illnesses struck hundreds of thousands of people, and claimed up to tens of thousands of lives. Children were especially vulnerable to the bacteria and viruses that led to such staggering […]
People with type 1 diabetes may have a different makeup of gut flora—the microbes that live in the human digestive tract—compared to that found in people without the disease. By studying the collection of genes within this microbiome and assessing their functions, researchers hope to understand if, and how, an altered microbiome contributes to autoimmunity and the onset of type 1 diabetes.
By Thania Benios In this first installment of a two-part series, Countdown takes you on a tour of your immune system and how it can turn against your body. In the second, we will give you a panoramic view of how JDRF is propelling the search for vaccines that can reset your immune system and […]
JDRF’s new partnership with Fast Forward and Axxam opens exciting new avenues for speeding the translation of basic research into drugs and treatments for type 1 diabetes. This research has the potential to negate the autoimmune process causing type 1 diabetes and multiple sclerosis, leading to cures for these diseases.
JDRF scientists have shed light on how regulatory T cells block the progress of diabetes. The findings highlight the important role of these cells in controlling autoimmunity and represent an important research advance that could be translated into therapies for people with type 1 diabetes.
The findings confirm the important role of B cells in triggering diabetes and also point to a potential new treatment: type 1 diabetes can be prevented in mice using a therapy that reduces the number of B cells.
Researchers are developing a novel oral vaccine for type 1 diabetes. Using “yeast shells” to deliver proteins and other agents, the vaccine is intended to interrupt the immune attack that causes diabetes, as well as silence key genes that contribute to inflammation and autoimmunity.